<DOC>
	<DOC>NCT00702026</DOC>
	<brief_summary>The purpose of this study is to determine whether a specifically designed multispecies probiotic decreases visceral hypersensitivity in IBS-patient (defined by an increased pain tolerance threshold). Moreover, the effect on general symptom scores and inflammatory and microbiological parameters will be studied.</brief_summary>
	<brief_title>The Effect of a Multispecies Probiotic on Hypersensitivity in Irritable Bowel Syndrome (IBS) Patients</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<mesh_term>Hypersensitivity</mesh_term>
	<criteria>Clinical diagnosis of IBS according to the Rome III criteria Increased visceral perception according to barostat measurements, defined as a pain tolerance threshold at smaller than or equal to 23 mmHg Age between 18 and 65 years BMI between 18.5 and 30 kg/m2 Known gastrointestinal diseases Major abdominal surgery Previous radiotherapy, chemotherapy Clinical significant systemic diseases Critically ill patients or patients suffering from severe acute pancreatitis Patients with organs failure Patients receiving enteral feeding Excessive alcohol intake (greater than 15 consumptions per week) (planned) pregnancy or lactation Use of pre, probiotics in the month before and during the study Use of antibiotics in the two months before and during the study Use of antidiarrhoea medication, antilaxatives or antiacid medication in the two weeks before and during the study Use of anti depressives (especially SSRI's) in the month before and during the study Use of other medication if less then one month on stable dosage</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Irritable Bowel Syndrome</keyword>
	<keyword>Hypersensitivity</keyword>
	<keyword>Probiotics</keyword>
	<keyword>Multispecies</keyword>
</DOC>